DE

462.21

+0.46%↑

CTAS

193.44

-1.67%↓

CSX

35.9

+0.39%↑

FDX

239.32

-1.47%↓

FAST

42.58

-1.8%↓

DE

462.21

+0.46%↑

CTAS

193.44

-1.67%↓

CSX

35.9

+0.39%↑

FDX

239.32

-1.47%↓

FAST

42.58

-1.8%↓

DE

462.21

+0.46%↑

CTAS

193.44

-1.67%↓

CSX

35.9

+0.39%↑

FDX

239.32

-1.47%↓

FAST

42.58

-1.8%↓

DE

462.21

+0.46%↑

CTAS

193.44

-1.67%↓

CSX

35.9

+0.39%↑

FDX

239.32

-1.47%↓

FAST

42.58

-1.8%↓

DE

462.21

+0.46%↑

CTAS

193.44

-1.67%↓

CSX

35.9

+0.39%↑

FDX

239.32

-1.47%↓

FAST

42.58

-1.8%↓

Search

Ocugen Inc

Cerrado

1.51 -2.58

Resumen

Variación precio

24h

Actual

Mínimo

1.47

Máximo

1.55

Métricas clave

By Trading Economics

Ingresos

611K

-15M

Ventas

-108K

1.4M

Margen de beneficios

-1,073.489

Empleados

95

EBITDA

724K

-13M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+424.69% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

188M

506M

Apertura anterior

4.09

Cierre anterior

1.51

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 oct 2025, 23:55 UTC

Acciones populares

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct 2025, 23:49 UTC

Ganancias

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct 2025, 21:40 UTC

Ganancias

Waste Connections 3Q Revenue Rises

21 oct 2025, 21:14 UTC

Ganancias
Principales Movimientos del Mercado

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

DraftKings to Launch Prediction Markets Platform

21 oct 2025, 20:38 UTC

Ganancias

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct 2025, 20:35 UTC

Ganancias

Capital One 3Q Sales, Profit Jump

21 oct 2025, 20:32 UTC

Ganancias

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 oct 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct 2025, 23:39 UTC

Charlas de Mercado

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct 2025, 23:36 UTC

Charlas de Mercado

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre Says This Forms Part of Capital Management Strategy

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct 2025, 22:54 UTC

Adquisiciones, fusiones, absorciones

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct 2025, 20:58 UTC

Charlas de Mercado
Ganancias

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

21 oct 2025, 20:43 UTC

Ganancias

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct 2025, 20:41 UTC

Ganancias

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct 2025, 20:29 UTC

Ganancias

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

424.69% repunte

Estimación a 12 Meses

Media 8.5 USD  424.69%

Máximo 15 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat